Cargando…
Shikimic acid as intermediary model for the production of drugs effective against influenza virus
This chapter explains the application of shikimic acid as preventive medicine for the outbreak of swine or Avian flu due to H1N1 virus. Shikimic acid (3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid), a natural organic compound, is generally utilized as a starting material for industrial synthesis...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153330/ http://dx.doi.org/10.1016/B978-0-12-817890-4.00016-0 |
_version_ | 1783521630359650304 |
---|---|
author | Priyanka Singh Gupta, Ena Neha Mishra Mishra, Pragya |
author_facet | Priyanka Singh Gupta, Ena Neha Mishra Mishra, Pragya |
author_sort | Priyanka Singh |
collection | PubMed |
description | This chapter explains the application of shikimic acid as preventive medicine for the outbreak of swine or Avian flu due to H1N1 virus. Shikimic acid (3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid), a natural organic compound, is generally utilized as a starting material for industrial synthesis of the antiviral oseltamivir, a drug against the H1N1 influenza virus. It is also an important intermediate in the biosynthesis of lignin, aromatic amino acids (phenylalanine, tyrosine, and tryptophan), and most alkaloids of plants and microorganisms. Plant and microbial sources are the only sources of shikimic acid. Being a deadly viral disease, influenza causes the death of around half a million people each year. A neuraminidase present on the surface of the virus is the most important factor for viral reproduction by contributing to the release of viruses from infected host cells and hence the treatment of influenza can only be possible by neuraminidase inhibitors. The neuraminidase inhibitors oseltamivir or Tamiflu derived from shikimic acid pathway have been found to be potent influenza viral neuraminidase inhibitors against most influenza strains. |
format | Online Article Text |
id | pubmed-7153330 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71533302020-04-13 Shikimic acid as intermediary model for the production of drugs effective against influenza virus Priyanka Singh Gupta, Ena Neha Mishra Mishra, Pragya Phytochemicals as Lead Compounds for New Drug Discovery Article This chapter explains the application of shikimic acid as preventive medicine for the outbreak of swine or Avian flu due to H1N1 virus. Shikimic acid (3,4,5-trihydroxy-1-cyclohexene-1-carboxylic acid), a natural organic compound, is generally utilized as a starting material for industrial synthesis of the antiviral oseltamivir, a drug against the H1N1 influenza virus. It is also an important intermediate in the biosynthesis of lignin, aromatic amino acids (phenylalanine, tyrosine, and tryptophan), and most alkaloids of plants and microorganisms. Plant and microbial sources are the only sources of shikimic acid. Being a deadly viral disease, influenza causes the death of around half a million people each year. A neuraminidase present on the surface of the virus is the most important factor for viral reproduction by contributing to the release of viruses from infected host cells and hence the treatment of influenza can only be possible by neuraminidase inhibitors. The neuraminidase inhibitors oseltamivir or Tamiflu derived from shikimic acid pathway have been found to be potent influenza viral neuraminidase inhibitors against most influenza strains. 2020 2020-01-24 /pmc/articles/PMC7153330/ http://dx.doi.org/10.1016/B978-0-12-817890-4.00016-0 Text en Copyright © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Priyanka Singh Gupta, Ena Neha Mishra Mishra, Pragya Shikimic acid as intermediary model for the production of drugs effective against influenza virus |
title | Shikimic acid as intermediary model for the production of drugs effective against influenza virus |
title_full | Shikimic acid as intermediary model for the production of drugs effective against influenza virus |
title_fullStr | Shikimic acid as intermediary model for the production of drugs effective against influenza virus |
title_full_unstemmed | Shikimic acid as intermediary model for the production of drugs effective against influenza virus |
title_short | Shikimic acid as intermediary model for the production of drugs effective against influenza virus |
title_sort | shikimic acid as intermediary model for the production of drugs effective against influenza virus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153330/ http://dx.doi.org/10.1016/B978-0-12-817890-4.00016-0 |
work_keys_str_mv | AT priyankasingh shikimicacidasintermediarymodelfortheproductionofdrugseffectiveagainstinfluenzavirus AT guptaena shikimicacidasintermediarymodelfortheproductionofdrugseffectiveagainstinfluenzavirus AT nehamishra shikimicacidasintermediarymodelfortheproductionofdrugseffectiveagainstinfluenzavirus AT mishrapragya shikimicacidasintermediarymodelfortheproductionofdrugseffectiveagainstinfluenzavirus |